Medically reviewed by Matthew Wosnitzer, MD Key Takeaways IgA nephropathy is a progressive disease where immune proteins ...

At the 18th International lgA Nephropathy Symposium (IIgANN 2025), 7 new abstracts based on real-world evidence of NEFECON® will be presented. The 18th IIgANN will take place in Prague, Czech Republic ...

IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...

Integrating these practical measures into routine care allows for more nuanced assessment of treatment success and timely intervention when therapy adjustments are needed. Stay ahead of policy, cost, ...

Early diagnosis and intervention create a return on investment model where up-front costs for screening, diagnosis, and early treatment yield substantial downstream cost savings while simultaneously ...

Please provide your email address to receive an email when new articles are posted on . NephCure will have a free, virtual town hall to bring attention to IgA nephropathy. The nonprofit will also ...

The event will highlight the Company’s CLYM116 program, a preclinical-stage monoclonal antibody targeting APRIL (A ...

May 11—(StatePoint) IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ages of 20 and 40, with an annual global incidence of 2.5 cases per ...

Medically reviewed by David Hampton, MD Key Takeaways IgA nephropathy often has no symptoms for years, but when they appear, ...

IgA nephropathy can raise some big questions. Will your symptoms be so mild you hardly notice a change in daily life? Will you need dialysis one day? Should you prepare for a kidney transplant 10 or ...

IgA nephropathy is hard to predict. But there’s one thing experts know. People with strong emotional and social support systems tend do better in the long run. And it’s best to live your life to the ...

This transcript has been edited for clarity. Matthew A. Sparks, MD: Hi. I'm Dr Matthew Sparks. Welcome to Medscape's InDiscussion series on chronic kidney disease (CKD). Today, we'll be discussing ...